Cited by 4,291Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchNeuroinflammation and Neurodegeneration Mechanisms

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, Dominic M., Klyubin, Igor, Fadeeva, Julia V., Cullen, William K., Anwyl, Roger, Wolfe, Michael S., Rowan, Michael J., Selkoe, Dennis J.·2002·Nature

Abstract

Although extensive data support a central pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, the amyloid hypothesis remains controversial, in part because a specific neurotoxic species of Abeta and the nature of its effects on synaptic function have not been defined in vivo. Here we report that natural oligomers of human Abeta are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell. Cerebral microinjection of cell medium containing these oligomers and abundant Abeta monomers but no amyloid fibrils markedly inhibited hippocampal long-term potentiation (LTP) in rats in vivo. Immunodepletion from the medium of all Abeta species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Abeta monomers but not oligomers, did not prevent the inhibition of LTP. Therefore, Abeta oligomers, in the absence of monomers and amyloid fibrils, disrupted synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid. Finally, treatment of cells with gamma-secretase inhibitors prevented oligomer formation at doses that allowed appreciable monomer production, and such medium no longer disrupted LTP, indicating that synaptotoxic Abeta oligomers can be targeted therapeutically.

Integrity signals

Registry

Crossref · 10.1038/416535a

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 31 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J.
Affiliations
  • Brigham and Women's Hospital (US)
  • Trinity College Dublin (IE)
Corresponding author
Selkoe, Dennis J.
Venue
Nature
Published
2002-04
Volume
416
Issue
6880
Pages
535-539
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2150999725
Cited by
4,291
References
31
Citations by year
2026: 83 · 2025: 83 · 2024: 115 · 2023: 120 · 2022: 110 · 2021: 135 · 2020: 162 · 2019: 148 · 2018: 161 · 2017: 194 · 2016: 196 · 2015: 196 · 2014: 215 · 2013: 227 · 2012: 270
FWCI
101.91
Type
journal article
Language
en
Open access
closed
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, amyloid-beta oligomers, Alzheimer's disease, amyloid hypothesis, hippocampal long-term potentiation, synaptic plasticity, synaptotoxicity, intracellular vesicles, gamma-secretase inhibitors, insulin-degrading enzyme, cerebrospinal fluid, neurotoxicity
MeSH terms
Alzheimer Disease, Animals, Cricetinae, Hippocampus, Humans, Insulysin, Microsomes, Endopeptidases, Protease Inhibitors, Recombinant Proteins, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, CHO Cells, Culture Media, Conditioned, Long-Term Potentiation, Rats, Amyloid Precursor Protein Secretases, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review